Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-24-116001
Filing Date
2024-11-08
Accepted
2024-11-08 17:58:50
Documents
1
Group Members
ABV SPV I GP LLCAVALON BIOVENTURES GP, LLCAVALON BIOVENTURES I, LPAVALON BIOVENTURES SPV I, L.P.AVALON VENTURES XI GP LLCBRADEN BOHRMANNJAY LICHTER, PH.D.KEVIN KINSELLARICHARD LEVANDOVSANFORD MADIGAN, PH.D.SERGIO G. DURON, PH.D.TIGHE REARDON

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm2427977d2_sc13da.htm SC 13D/A 270928
  Complete submission text file 0001104659-24-116001.txt   272946
Mailing Address 1134 KLINE STREET LA JOLLA CA 92037
Business Address 1134 KLINE STREET LA JOLLA CA 92037 8583482180
Avalon Ventures XI, L.P. (Filed by) CIK: 0001652901 (see all company filings)

EIN.: 474748883 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92596 | Film No.: 241442349
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)